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Abstract: Melatonin is a tryptophan-derived molecule with pleiotropic activities which is produced
in all living organisms. This “sleep” hormone is a free radical scavenger, which activates several
anti-oxidative enzymes and mechanisms. Melatonin, a highly lipophilic hormone, can reach body
target cells rapidly, acting as the circadian signal to alter numerous physiological functions in the body.
This indoleamine can protect the organs against a variety of damaging agents via multiple signaling.
This review focused on the role played by melatonin in the mechanism of esophagoprotection,
starting with its short-term protection against acute reflux esophagitis and then investigating the
long-term prevention of chronic inflammation that leads to gastroesophageal reflux disease (GERD)
and Barrett’s esophagus. Since both of these condition are also identified as major risk factors for
esophageal carcinoma, we provide some experimental and clinical evidence that supplementation
therapy with melatonin could be useful in esophageal injury by protecting various animal models
and patients with GERD from erosions, Barrett’s esophagus and neoplasia. The physiological aspects
of the synthesis and release of this indoleamine in the gut, including its release into portal circulation
and liver uptake is examined. The beneficial influence of melatonin in preventing esophageal injury
from acid-pepsin and acid-pepsin-bile exposure in animals as well as the usefulness of melatonin and
its precursor, L-tryptophan in prophylactic and supplementary therapy against esophageal disorders
in humans, are also discussed.
Keywords: melatonin; L-tryptophan; reflux esophagitis; gastroesophageal reflux disease; Barrett’s
esophagus; inflammation; esophageal blood flow; esophageal adenocarcinoma
1. Anti-Reflux Esophageal Barrier and Pathogenesis of Esophageal Damage Induced by
Gastroduodenal Reflux
Gastroesophageal reflux disease (GERD) is a multifactorial process and one of the most common
diseases of the upper gastrointestinal tract (GI-tract) in humans [1–3]. This disorder is the logical
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consequence of the failure of the physiological anti-reflux barrier to protect against frequent and
abnormal load of gastroesophageal reflux of acid or alkaline content, or both. The pathogenesis of
GERD is complex, resulting from an imbalance between defensive factors protecting the esophagus
such as the anatomical anti-reflux barrier, esophageal acid clearance, the mucosal epithelial component
of the esophageal barrier and aggressive factors from the stomach and duodenum [4–6]. Important
aggressive endogenous factors of gastric origin, which affect esophageal mucosa during gastric
reflux, predominantly include the gastric acid and the pepsin activity [7,8]. At the cellular level,
the development of inflammatory alterations, known as reflux esophagitis (RE) is due to hydrogen ion
diffusion into the mucosa, leading to tissue acidification and necrotic mucosal damage. It has been
demonstrated that acid alone induces minor injury of esophageal mucosa at pH of less than 3. However,
the acid combined with even small amounts of pepsin results in potent damage of the mucosal lining,
increases the permeability of esophageal mucosa to hydrogen ions, creates morphologic changes
to the esophageal mucosal structure and local hemorrhage [8–10]. Thus, the ability of pepsin to
induce esophageal mucosa injury is acid-dependent, with maximal damage below pH 3 [5–8]. Along
with acid and pepsin, the duodenal content containing bile acids, trypsin and hyper osmolality
may be injurious to the esophageal mucosa during the presence of duodenogastric reflux [9,10].
Experimental studies have demonstrated that bile acids induce mucosal injury of greater magnitude
when the combination of hydrochloric acid and pepsin have occurred [10]. Among aggressive factors
of exogenous origin, cigarette smoking, alcohol and non-steroidal anti-inflammatory drugs (NSAIDs)
such as aspirin, naproxen, indomethacin, and ibuprofen have been identified as risk factors for
the development of erosive esophagitis in humans [11–14]. Development of RE is sometimes also
potentiated by simultaneous steroid use. Among NSAIDs, the most popular drug, aspirin has
increased the susceptibility of the esophageal mucosa to the injurious action of acid and pepsin
in experimental animals and humans [15,16]. The basic level of esophageal defense against acid
damage consists of natural anti-reflux mechanisms, which are created by special physiological
properties of the gastroesophageal junction [4,17]. The lower esophageal sphincter (LES), is considered
to play an essential role as the mechanical barrier that prevents the backflow of gastric contents
from the stomach into the esophagus [6]. The accumulated evidence indicates that abnormalities
in the LES, such as transient sphincter relaxation, contribute to the development of reflux of
gastric content into the esophagus. The next level of esophageal luminal defense against reflux
damage is primarily achieved by luminal acid clearance which is accomplished by esophageal
peristalsis, removal of the esophageal contents, and neutralization of esophageal luminal acidity
by bicarbonate secreted locally by submucosal glands or delivered with swallowed saliva [5,18].
The esophageal mucosal defense includes tissue resistance, which depends upon the presence of
pre-epithelial, epithelial, and post-epithelial defensive mechanisms consisting of either, or both the
morphological and functional components [17,18]. The morphological components include the cell
layers of esophageal mucosa, which create a relatively tight epithelium with high resistance to ionic
movement. The pre-epithelial functional components of mucosal resistance include mucus and
unstirred water layers with bicarbonate ions located on the surface of the esophageal epithelium to
neutralize and extrude hydrogen ions [5,6,19]. Functional defense components include the buffering
capacity of negatively charged proteins, bicarbonate ions, and H+ extrusion processes [18,19].
The esophageal protection against the damaging effects of acidic and acid-alkaline refluxate
contents depends upon the buffer capacity of the pre-epithelial and epithelial (intraepithelial)
mechanisms. These mechanisms involve both the histological architecture of the mucosal membrane
and the functional physiological properties of esophageal mucosa preventing the back diffusion of
hydrogen ions [17–19]. Post-epithelial defense mechanisms provided by adequate mucosal blood flow
as well as buffering capacity are detrimental in the regulation of the local acid-base balance [20,21].
In particular, the undisturbed esophageal blood flow (EBF) seems to be a critical physiological measure
responsible for the proper functioning of the pre-epithelial and for the intraepithelial mechanisms
ensuring the protective ability of the esophageal mucosal barrier against the damaging action of
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acid, pepsin and bile [21]. Moreover, adequate blood flow is responsible for the supply of oxygen
and energy substitutes and the distribution of neurohormonal and humoral factors controlling the
local blood flow. Studies in the past have shown that the local blood flow in the esophageal mucosa
plays an essential role in maintaining optimal pH in response to mucosal exposure to gastric acid
contents [20–22]. Indisputably, there is a close relationship between EBF, esophageal function and
protective mechanisms in the esophageal mucosa. Sudden limitation or cessation of EBF may result in
mucosal esophageal damage due to both hypoxia and the damaging effects of the reperfusion which
follows the ischemia. The damaging effect of ischemia followed by rapid reperfusion is attributable
to the enhancement in generation of highly cytotoxic reactive oxygen metabolites (ROM) [23,24].
Interestingly, the extent and depth of mucosal damage depends on the time and degree of complete
cessation or reduction of EBF. The regulation of EBF depends on systemic nervous mechanisms and
local hormonal-humoral factors [21–25]. Under physiological conditions, the EBF increases in response
to increased secretory activity of the esophageal mucosa and during incidental acid reflux episodes of
gastric content [23–25]. This local hyperemia is responsible for the bicarbonate supply which creates
and maintains the alkaline pH of the mucous membrane surface and provides rapid neutralization of
the acid load during reflux episodes [20,24,25].
The neurogenic control of esophageal integrity involves the activity of capsaicin-sensitive sensory
nerves releasing vasoactive neuropeptides, which are known to ensure the protection of the esophageal
epithelial barrier mucosa against damaging factors [26,27]. Esophageal sensory fibers are carried by
vagal and spinal primary unmyelinated afferent nerves containing and releasing vasodilatory peptides
such as calcitonin gene-related peptide (CGRP), substance P (SP) and vasoactive intestinal peptide
(VIP) [26–28]. They are implicated in orthodromic transmission of sensory information from esophageal
mucosa to the central nervous system [26–28]. The main physiological role of capsaicin-sensitive
sensory nerves is the modulation of the esophageal mucosal hyperemia in response to physiological
factors and to damaging factors due to stimulation of mucosal acid-sensing sensory endings [21,28,29].
In response to stimulation of these mucosal acid-sensing sensory endings, predominantly by the
reflux of gastric acid to the esophagus, an increase in EBF has been observed [29]. Numerous
vasodilatory locally released sensory neurotransmitters factors such as CGRP and VIP, as well as
endothelium-derived gaseous molecules nitric oxide (NO) and hydrogen sulfide (H2S) were implicated
in the mechanism of esophageal mucosal hyperemia [9,16,27,28]. Previous studies have strongly
supported the importance of neuropeptides released from capsaicin-sensitive sensory nerve endings
in the mechanism of esophageal integrity and mucosal defense [27–29]. Moreover, hyperemia evoked
by the reflux of gastric juice in rat esophagus was inhibited by ablation of capsaicin-sensitive sensory
nerves by neurotoxic dose of capsaicin, this latter effect being reversed in part by the treatment of
capsaicin-sensory inactivated rats with exogenous CGRP [9,26,28].
2. Reflux Esophagitis in Animal Models and the Process of Progression of Mucosal Changes
Caused by Reflux Esophagitis into Barrett’s Esophagus and Esophageal Adenocarcinoma
Several animal models in vivo have been developed to reproduce the mechanism of both acute
and chronic inflammation of esophageal mucosa. One of these methods allows inducing acute
inflammation, which has been fully described by Nagahama et al. [7]. The major rationale behind
this method is from one side, the reduction of the gastric capacity by ligation of the reservoir part
of the stomach, but from the other side, the pylorus ligation to prevent the passage of the gastric
contents into duodenum. This acute method, which facilitates the return of gastric juice into esophagus,
achieves the induction of acute hemorrhagic lesions of the esophageal mucosa in the relatively short
time of a few hours [7]. Experimental in vivo methods causing chronic esophageal inflammation are
strictly dependent upon the continuous contact of gastric and/or duodenal contents with esophageal
mucosa. The method introduced by Tsui et al. [30] is a modification of Tsukimi and Okabe’s method of
inducing chronic gastric ulceration in the stomach [31]. According to the method used by Tsui et al. [30],
esophageal necrosis is initially produced by 100% acetic acid application onto an esophageal segment
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in a standardized area with a diameter of 3 mm for 60 s. The method created by Omura et al. [32] is
based on the surgical placement of a standardized girdle in the antro-duodenal area which impedes
the passage of gastric contents to the duodenum. The method published by Nishijima et al. [33] aims
to create connections between the duodenum and esophagus which allow chronic passage of the
gastro-duodenal contents through esophagus. The complete gastrectomy is performed with stitching
of the end of duodenum and creation of the end-to-side connection between the distal esophagus and
jejunum at the standardized distance from the Treitz ligament. The chronic passage of gastroduodenal
contents into the esophagus can be also obtained using the surgical method [34]. The creation of the
esophagoduodenal anastomosis is made by cutting the esophagus from the stomach at the level of the
lower esophagus sphincter, stitching the stomach stump and then stitching the distal stump of the
esophagus to the free wall of the duodenum at a distance of 1 cm from the pylorus [34]. Naito et al. [10]
also developed a surgical method allowing the chronic passage of duodenal or gastro-duodenal
contents through the esophagus. This method includes a 7 mm oblong cut on both the free anterior
wall of the esophagus and the duodenum and performing the connections between the walls of the
esophagus and duodenum using the side-to-side method. A method that allows chronic administration
of test substances (drugs), that are continually infused, has also been developed. Briefly, one end of the
esophageal cannula is placed in a subcutaneous pump allowing the test substance to be administered
in continuous infusion at a certain rate via an operatively placed cannula into the esophagus directly
into esophageal lumen [35].
Previous experimental and clinical studies have provided well documented data that RE is the
main risk factor of Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC) [36,37]. The chronic
irritation of esophageal mucosa caused by gastric or gastroduodenal contents are the major risk factors
in the pathogenesis of these diseases. It is still unclear why some patients with GERD suffer only from
RE, while others develop metaplastic and dysplastic esophageal changes [36–38]. BE is a condition
based on a histologically proven change of esophageal epithelium to the specialized intestinal-type
glandular epithelium [39,40]. The current definition of BE is defined by the endoscopic and histological
criteria because diagnosis of BE requires validation by histological analysis of endoscopically obtained
biopsy specimens [38]. It is well documented that BE patients are at higher risk of progression
to esophageal dysplasia and EAC [39–41]. It is estimated that BE metaplasia increases the EAC
risk by about 40-fold [41,42]. During the last four decades, the incidence for EAC has dramatically
increased [41,42]. Clinical studies provided well documented evidence that esophageal reflux of bile
acids is also an important risk factor in the development of BE and EAC [42,43]. The exposure of
esophageal epithelial cells to short, repeated episodes of bile acid reflux results in breaking of the
epithelial barrier and stimulates cell proliferation. The rupture of cell membrane and cellular tight
junctions in response to hydrogen ions and activated pepsin results in the mucosal and submucosal area
of acid and pepsin penetration causing more severe hemorrhage and ulcerative damage. This combined
action of acid and pepsin promotes esophageal epithelial differentiation to specialized intestinal-type
glandular epithelium [44–46]. Besides gastric acid and pepsin, esophageal chronic reflux of bile acids
and salts also predispose esophageal mucosa to development of BE and EAC [45], but the exact
mechanisms underlying the transformation from specialized intestinal-type glandular epithelium
to BE and EAC are still not fully understood and have become the subject of experimental and
clinical investigations.
There are two isoforms of cyclooxygenases (COX) involved in the process of inflammation and
tumorigenesis. The constitutive COX-1 is homeostatically expressed in most tissues while the inducible
isoform COX-2 activated by numerous cytokines is detectable mostly in inflamed tissues [46,47].
The experimental and clinical evidence indicates the major role of COX-2 derived prostaglandins (PG)
in the progression of specialized intestinal-type glandular epithelium to BE and EAC [48]. The process
of carcinogenesis in animals and humans has been strongly linked to the COX-2 overexpression
and the PG generation associated with decreased cell adhesion, increased cell proliferation and
metastases formation, and the enhancement in angiogenesis, decreased apoptosis and increased
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immunosuppression [48–52]. The treatment with selective COX-2 inhibitors and NSAIDs has been
shown to reduce the risk of EAC development, however, the therapeutic usefulness of these drugs
is questionable because these COX-2 inhibitors were reported to exert local and systemic adverse
effects [53]. According to recent consensus, BE is considered as an end-stage of GERD because
this disorder is significantly more frequent among patients with RE than in the general population.
Even though BE is commonly recognized as a condition preceding the development of adenocarcinoma
of the gastroesophageal junction, the detailed mechanism of progression of RE into BE and esophageal
oncogenesis remains largely unknown. It is widely accepted that clinically, BE involves at least 3 cm to
fulfill the diagnostic criteria of so-called “classical” or “long segment” BE [54]. Currently, if the lesions
are found in a segment shorter than 3 cm they belong to a “short segment” BE [54,55]. If the metaplasia
is present and only manifest with irregularities or patches of properly localized Z-line, this particular
case is referred as “ultra-short” BE [56]. Progression of Barrett’s metaplasia into EAC occurs as
a result of chronic irritation of the mucosa by refluxate containing bile, since an apparent correlation
between the bile salts concentration in refluxate and the degree of esophageal mucosal damage has
been proposed [55–57]. The treatment of BE is mainly based on the chronic use of proton pump
inhibitors (PPI) that reduce esophageal reflux acid gastric content and the surgical procedures aimed
at restoring high pressure zones limiting the exposure of distal esophagus to irritating gastroduodenal
refluxate [57,58]. Moreover, both methods are also used in combination with various endoscopic
mucosal ablation techniques such as argon plasma beam coagulation (APC). All these procedures
have been shown to enhance the process of re-epithelialization in the region of the GE junction [59].
There are no uniformly accepted standards of management of BE at present. It is proposed that the
combined treatment of GERD with surgical ablation of metaplastic mucosa should minimize the risk
of carcinogenesis.
3. Role of Melatonin in Esophagoprotection and Prevention of Chronic Esophageal Disorders
Melatonin, an indole enzymatically derived from L-tryptophan, is the most versatile and
ubiquitous hormonal molecule produced in all animal species and also in some plants [60]. Melatonin
is synthesized from tryptophan in the mammalian pineal gland, however, a similar biosynthetic
pathway of this indoleamine has been described in plants. In vertebrates, melatonin production is
driven by the circadian rhythm with a peak at night [61]. Since melatonin is rapidly absorbed from the
GI-tract the presence of this indoleamine and/or its precursor L-tryptophan in plant derived products
is of particular importance. Fruits such as Citrus fresh and their juices are highly consumed worldwide.
In Citrus genus plants, De Masi et al. [62] have reported that the labeled tryptophan is decarboxylated
into tryptamine, the precursor of serotonin and melatonin. Furthermore, these investigators have
revealed the existence of tryptophan decarboxylase (TDC) gene by in silico analysis [62]. In humans,
melatonin is synthesized and secreted primarily by the pineal gland in response to environmental
light/dark cycles, activated by suprachiasmatic nuclei (SCN), the major circadian oscillator, regulating
the circadian rhythm of numerous biological functions. Previous studies revealed that the biosynthesis
and plasma levels of this hormone are attenuated by age and various neurodegenerative, metabolic
and cardiovascular diseases [63,64]. Melatonin acts on the target cells either directly or via G-protein
coupled membrane receptors, including melatonin MT1R, MT2R and MT3R known to trigger several
intracellular messengers such as cAMP, cGMP, and cytosolic Ca2+ concentration [65]. Similar to
pineal gland cells (pinealocytes), the entero-endocrine (EE) cells present in GI-tract mucosa are the
major source of intestinal melatonin [64,65]. After the termination of the biosynthesis process in EE
cells, melatonin is immediately transported to the extracellular fluid, gastrointestinal lumen and its
concentration increases in systemic circulation. From all these compartments it easily passes through
all the membranes [66] (Figure 1) and can act on target cells in the GI-tract in both a paracrine and
an endocrine manner when released into the portal vein [67]. Huether et al. [68] demonstrated that
oral application of L-tryptophan causes a rapid elevation of circulating melatonin in rats. This rise
in plasma melatonin levels was higher than that obtained after intraperitoneal administration of this
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indoleamine and this increment was abolished by portal vein ligation. Interestingly, this increase in
plasma melatonin levels was unaffected by pinealectomy, indicating that the GI-tract is the major
source of circulating melatonin after an oral application of L-tryptophan [68,69]. These studies also
revealed that GI-tract mucosa contains melatonin under fasting conditions, however, its content in the
GI-tract increases markedly after meal ingestion or consumption of a tryptophan-rich diet [69].
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Figure 1. The mechanistic effects of endogenous melatonin produced in the pineal gland or
gastrointestinal tract (GI-tract) and exogenous melatonin in attenuation of inflammatory reaction
and protection of GI-organs including the esophagus, stomach and intestine.
Several studies using immunohistochemistry and radioimmunoassay (RIA) techniques, validated
by HPLC, have confirmed the presence of melatonin in the mucosa of the gut and showed that EE cells
are the major source of melatonin in the GI-tract [64,70]. High concentrations of melatonin in both the
gastric and duodenal mucosa and large amounts of it excreted into the bile in humans were confirmed
by studies performed by Messner et al. [71]. Moreover, the plasma levels of melatonin in portal
circulation greatly exceeds that found in peripheral bloo at various points of time in the circadian
period, but especially after food intake [66 . The fore, it has been proposed tha m latonin ac s as the
universal biological sig al mediating the inter- rgan cross-talk between the GI-tract organs and the
liver [72–74] (Figure 1). Melatonin production and its release from the pineal gland remains under
photoperiodic control, while its concentration in the gut depends mainly on food intake and could
serve as an example of regulation through the negative feedback mechanisms [73]. The concentration
of major enzymes involved in melatonin synthesis, namely hydroxyindole-O-methyltransferase
(HIOMT) and N-acetyltransferase (NAT) as well as melatonin concentrations in GI-tract mucosa
have been shown to exceed by 100–400 times those in the blood plasma levels. This increase in GI-tract
melatonin synthesis is potentiated mainly after intake of protein meals containing L-tryptophan [74].
Thus, the enhanced production of melatonin in the GI-tract, as well as a L-tryptophan diet, contributes
to the maintenance of this indoleamine concentration in peripheral blood [74–76] (Figure 2). Studies
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using a 2-[125I]-labeled melatonin revealed the binding sites for melatonin distributed in tissues of
rodents and humans [68,74–76]. The binding sites for melatonin have been identified in all GI-tract
tissues and the hyperbolic shape of specific binding curves confirmed that the radio-ligand is bound to
a saturable number of binding sites possessing a single family [76]. Importantly, the tissue melatonin
concentrations measured by RIA were about 20 times lower in the gut when compared to the pineal
gland [77]. Interestingly, L-tryptophan administered orally raised melatonin not only in the pineal
gland, but also in the GI-tract and the liver by about 6 and 10-fold, respectively [78]. L-tryptophan also
increased the circulating levels of melatonin, mainly in the portal circulation. The local alterations in
melatonin levels in the GI-tract following tryptophan application were unaffected by pinealectomy
but significantly reduced by the partial occlusion of the portal vein [29,66,75,76,78].
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Figure 2. Chromatographic analysis of the tissue homogenate solution recorded by fluorescence
detection presenting the conversion of L-tryptophan administered intragastrically in a dose of
100 mg/kg into melatonin in rat gastrointestinal tract. Chromatograms show particular peaks of
melatonin derived from L-tryptophan in gastric mucosal tissue homogenates.
These studies provided strong evidence that the GI-tract, particularly the stomach, duodenum
and the hepatobiliary system, exhibits a high biosynthetic activity for melatonin, especially after
tryptophan administration or high protein meal ingestion [29,78]. Large amounts of extra-pineal
melatonin have been detected in tissues that are continuously exposed to a hostile environment, such as
stress conditions affecting the GI-tract mucosa. The major function of locally produced melatonin
in the GI-tract is to strengthen the esophageal and gastric mucosal barrier and to afford protection
against the damage to esophageal and gastric mucosa against the deleterious action of various stressors
including mucosal irritants of endogenous or exogenous origin, such as cytotoxins present in the
digested food, alcohol consumption and NSAIDs ingestion [72,73,77,78]. The upper GI-tract, especially
the esophagus is exposed to a variety of irritants entering the gut together with ingested food or
local stressors including acid, pepsin and/or bile salts refluxed to the esophageal compartment
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with gastroduodenal content [29,78,79]. Nowadays, GERD without or with erosive changes in
esophageal mucosa (non-erosive reflux disease (NERD) is often diagnosed as a condition that may
lead to dangerous clinical complications, such as chronic esophagitis, esophageal ulcers, strictures,
Barrett’s esophagus or Barrett’s adenocarcinoma [79,80]. Interestingly, Pereira et al. [79] reported
that patients who suffered from GERD, showed remarkable remission of GERD symptoms following
dietary supplementation of melatonin and L-tryptophan. The clinical remission of GERD symptoms
and the number of patients’ complaints were comparable with those recorded in patients treated with
PPI such as omeprazole [79]. Thus, melatonin or its precursor, L-tryptophan, accelerated the remission
of GERD symptoms without any significant side effects, and that is why melatonin or L-tryptophan
were postulated as possible alternative medications in GERD therapy [81,82]. Studies in rats revealed
the presence of immunostaining for melatonin in the esophagus, particularly after administration of
exogenous melatonin [75]. Marked and widespread esophageal lesions, including perforation of the
esophageal walls, have been observed in experimental models of GERD in anesthetized rats when
their esophagi were perfused daily for 2 h with acid-pepsin solution with or without addition of the
bile [81]. Pretreatment with melatonin protected the esophageal mucosa against the formation of acute
mucosal lesions, indicating the potent esophagoprotective activity of this hormone [81]. The activation
of COX-PG and NOS-NO systems as well as the stimulation of capsaicin-sensitive afferent nerve
endings by melatonin were implicated in the mechanism responsible for the protective action of this
indoleamine [81]. Interestingly, pretreatment of rats either with indomethacin, the non-specific blocker
of COX-1/COX-2, with NG nitro-L-arginine (L-NNA), a non-specific suppressor of eNOS activity
or with capsaicin, a neurotoxin known to induce e the functional ablation of the afferent sensory
nerves, also abrogated the esophagoprotective effects of melatonin [81]. Moreover, indomethacin,
used at a dose suppressing the esophageal mucosal generation of PGE2 by about 75%, or L-NNA
which blunted the plasma nitrate/nitrite (NOx) level by about 60%, were more effective in suppressing
the generation of mucosal PGE2 and plasma levels of NOx, respectively, in animals treated with
melatonin than in vehicle-treated control rats [81]. The functional ablation of sensory nerves by
capsaicin has been found to abolish melatonin-induced esophagoprotection [9,29,81]. Moreover,
capsaicin deactivation of sensory nerves significantly attenuated the melatonin-induced increase in
plasma NOx levels. Therefore, it was concluded that sensory nerves contribute to melatonin-induced
esophagoprotection by releasing CGRP and NO due to NOS activation [29,81]. Previous studies using
radiolabeled melatonin agonist 2-[125I] indolomelatonin documented the presence of melatonin binding
sites in esophageal mucosa [75,76]. Therefore, it was proposed that the beneficial effects of exogenous
melatonin could be attributed to its interaction with melatonin (MT) receptors [72,73]. The attenuation
of melatonin-induced esophagoprotective action was linked with an impairment of mucosal blood flow
caused by the pretreatment with COX or NO inhibitors such as indomethacin or L-NNA, respectively,
and deactivation the sensory nerves by capsaicin. Thus, this evidence indicates that melatonin exerted
its protective activity by increasing the EBF, possibly due to the synergistic activity and cooperative
action of mucosal vasoactive mediators PG, NO and CGRP [81]. This notion is supported by the
observation that pretreatment with indomethacin or LNNA abolished the esophagoprotective effect
of melatonin that was accompanied by the fall in mucosal PGE2 generation and the amelioration
of NO biosynthesis, respectively. These data indicate that PGE2 and NO were the major effectors
responsible for protective activity of melatonin against acid-pepsin and bile perfusion in rats. Moreover,
the capsaicin-induced deactivation of sensory nerves resulted in the most severe damage to esophageal
mucosa exposed to the irritating action of acid and pepsin [83]. Since capsaicin suppresses the release
of CGRP from sensory nerves that stimulates NOS expression, the activity of this enzyme and the
NO biosynthesis, it is reasonable to assume that NO plays a central role in the mechanism of the
esophagoprotection by this indoleamine. This is in keeping with the observation that reduced plasma
levels of NOx in capsaicin denervated rats were reversed in part by co-treatment with melatonin or
L-tryptophan [81]. In another experimental model of GERD, the effect of exogenous administration
of melatonin and melatonin-derived endogenously from L-tryptophan with that of pantoprazole or
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ranitidine was studied in rats with RE evoked by two ligations, namely, (1) pylorus ligation and
(2) the ligation of the limiting ridge between the forestomach and the corpus [29]. Four hours after
the onset of gastric reflux induction, the mucosal lesions associated with edema of the submucosa
and the fall in EBF was observed [29]. Histologically, the infiltration of numerous neutrophils has
been noticed [29]. Pretreatment with melatonin or L-tryptophan or pretreatment with pantoprazole
significantly reduced the lesion index (LI) and raised the EBF. Pinealectomy, which significantly
decreased plasma levels of melatonin, augmented esophageal mucosa LI and these effects were
attenuated in the pinealectomized animals pretreated with melatonin or L-tryptophan [29]. Luzindole,
the MT2 receptor antagonist [65], abolished the melatonin-induced esophagoprotection and the rise in
the EBF induced by treatment with this indoleamine. L-NNA or capsaicin, that by itself exacerbated
esophageal injury and decreased EBF, also counteracted this esophagoprotection and the accompanying
rise in EBF evoked by this indoleamine. Both these effects were restored with exogenous L-arginine and
CGRP given in combination with melatonin. The increased expression of mRNAs for proinflammatory
cytokines such as IL-1β and TNF-α and the rise in plasma IL-1β and adhesion molecules have been
observed in experimental models of esophagitis [84], and these alterations in esophageal mucosa were
significantly attenuated by pretreatment with melatonin and L-tryptophan [29]. These results have
confirmed that melatonin-induced esophagoprotection against acid reflux-induced esophageal damage
is mediated via the indoleamine activation of MT2 receptors, NO and CGRP released from sensory
nerves and the downregulation of expression and release of proinflammatory cytokines TNF-α and
IL-1β [29,71,82]. Melatonin has been recognized as a potent ROM scavenger and antioxidant capable of
influencing all major physiological functions of the GI-tract including secretion, motility, digestion and
intestinal absorption. Melatonin was reported as a beneficial molecule in scavenging the ROM. Besides
exhibiting anti-oxidizing and anti-inflammatory actions, melatonin has also been shown to inhibit
the formation of metalloproteinases-3 and -9, both strongly implicated in the pathogenesis of upper
GI-tract injury and RE [78] (Figure 3). Under normal physiological conditions, the esophagoprotective
activity of melatonin against GERD could be partly explained by its inhibitory influence on gastric acid
secretion resulting in an increase in gastrin release [83]. Gastrin is known to increase the contractile
activity of the lower esophageal sphincter (LES), thus reducing the incidence of gastro-esophageal
reflux [83,84]. This may imply that melatonin exerts its beneficial gastro- and esophagoprotective
actions also via melatonin receptors directly located on gastric G cells releasing gastrin, however,
this hypothesis requires confirmation in further studies.
Although RE pathophysiology is multifactorial, transient LES relaxations may play an important
role in the mechanism in esophageal dysfunction [85]. Frequently, patients with RE experience an
increase in acid and activated pepsin exposure of esophageal mucosa compared to healthy control
groups. However, there are also patients who do not experience an increase in the number of
transient LES relaxations in comparison to controls [85]. In another study, the esophageal Het-1A
monolayer barrier function in vitro was investigated by measuring transepithelial resistance (TER) and
FITC-dextran paracellular permeation with or without acid treatment [86]. In a series of experiments
in vitro utilizing the esophageal epithelial cells, the increased expression and activity of myosin light
chain kinase (MLCK) and extracellular signal-regulated kinase (ERK) phosphorylation were observed,
but upon acid treatment, the Het-1A monolayer permeability was increased [86]. When the Het-1A
monolayer was pretreated with melatonin before the addition of acid to the culture, the permeability
and the expression and phosphorylation of MLCK and ERK were markedly decreased [86]. It was
concluded that melatonin may preserve the esophageal epithelial cell monolayer barrier functions
in response to acid challenge by suppressing the transcription, translation and activity of MLCK
through ERK1/2 signal transduction [86]. Thus, this study suggested that melatonin application in
RE patients might be of potential clinical benefit in strengthening the integrity and permeability of
surface epithelial esophageal cells [86]. This notion can be supported by the fact that older people are
at a higher risk of complications from persistent RE due to the fall in melatonin production in elderly
patients [87,88]. It is also of interest that patients presenting with upper digestive tract disorders such
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RE or duodenal ulcer show reduced plasma levels of melatonin [89]. This suggests that deficiency
of this indoleamine may weaken esophageal and/or duodenal barrier mechanisms, thus exerting
deleterious effects on the upper GI-tract mucosa [89]. This corroborates previous studies in humans
with dietary supplementation containing melatonin and tryptophan, in which complete recovery from
RE symptoms was observed after such treatment [89].
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  10 of 16 
 
barri r mechanisms, t us ex rting deleteri us effects on the upp r GI-tract m cosa [89]. This 
corrobor tes previous studies i  humans with dietary su plementation ontaining m latonin and 
tryptophan, in hich complete recovery fro  RE symptoms was observed after such treatment [89].  
 
Figure 3. A summary of the pleiotropic actions of melatonin in gastrointestinal and 
extra-gastrointestinal organs. Besides regulating the circadian rhythm, melatonin plays an important 
role in the mechanism of protection of gastrointestinal organs including the esophagus, stomach and 
intestine. 
Melatonin is a natural compound and its safety and tolerability as a dietary supplement that 
mimics the function of endogenous melatonin in humans, has been well documented [87,88]. 
However, some adverse effects of the short-term or long-term melatonin administration should also 
be considered. For instance, the different administration times of this indoleamine, which is 
distributed in many countries over the counter, can influence the impact the compound has on 
circadian rhythm. For instance, the morning administration of melatonin can delay circadian rhythm 
and delay the onset of evening fatigue [89,90]. Melatonin was reported to improve sleep latency but 
the evidence for the overall improvement in sleep in humans is limited [91]. Still the potential 
concerns of daytime drowsiness increases when the administration of melatonin in daily hours is 
considered [92]. Residual daytime sedation, tiredness at rising, and increased sleep disruption with 
the use of melatonin have also been reported [93]. On the other hand, no convincing reports of local 
or systemic GI-tract adverse effects have been linked with chronic melatonin ingestion in humans, 
except for one incidence where it exacerbated the symptoms of the Crohn’s disease [94]. In several 
studies on melatonin safety, no serious adverse reactions with melatonin administered even in large 
pharmacological doses were reported [95]. 
Long term use of PPIs has been shown to be effective in GERD and BE patients [80,87,96]. These 
antisecretory drugs were shown to provide pain relief, prevent stricture formation and are relatively 
well tolerated and safe [83,88,96]. However, the common side effect of long term PPI administration 
Figure 3. A summary of the pleiotropic actions of melatonin in gastrointestinal and extra-gastrointestinal
organs. Besides regulating the circadian rhythm, melatonin plays an important role in the mechanism of
protection of gastrointestinal organs including the esophagus, stomach and intestine.
Melatonin is a natural compound and its safety and tolerability as a dietary supplement
that mimics the function of endogenous melatonin in humans, has been well documented [87,88].
However, some adverse effects of the short-term or long-term melatonin administration should also be
considered. For instance, the different administration times of this indoleamine, which is distributed
in many countries over the counter, can influence the impact the compound has on circadian rhythm.
For instance, the morning administration of melatonin can delay circadian rhythm and delay the onset
of evening fatigue [89,90]. Melatonin was reported to improve sleep latency but the evidence for
the overall improvement in sleep in humans is limited [91]. Still the potential concerns of daytime
drowsiness increases when the administration of melatonin in daily hours is considered [92]. Residual
daytime sedation, tiredness at rising, and increased sleep disruption with the use of melatonin have
also been reported [93]. On the other hand, no convincing reports of local or systemic GI-tract adverse
effects have been linked with chronic melatonin ingestion in humans, except for one incidence where
it exacerbated the symptoms of the Crohn’s disease [94]. In several studies on melatonin safety,
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no serious adverse reactions with melatonin administered even in large pharmacological doses were
reported [95].
Long term use of PPIs has been shown to be effective in GERD and BE patients [80,87,96].
These antisecretory drugs were shown to provide pain relief, prevent stricture formation and are
relatively well tolerated and safe [83,88,96]. However, the common side effect of long term PPI
administration is hypergastrinemia followed by the upregulation of COX-2 expression and an increase
in PG activity observed in BE [88]. These effects could be mediated directly by gastrin acting via CCK2
receptor [97–99] or via an indirect pathway due to induction of EGF that in turn, could upregulate the
expression of COX-2 due to EGF/TGFα receptor transactivation [97,100]. It is of interest that GERD
can be a “physiological” process on a daily basis frequently observed in infants and that it becomes
exacerbated by the structural and functional immaturity of the gastroesophageal junction, recumbent
position and food consistency, including a liquid milk-based diet [101]. Further studies are still needed
to prove whether acid suppressive drugs (PPI, i.e., pantoprazole) with or without selective COX-2
inhibitors (i.e., celecoxib) to inhibit the inducible COX-2 activity could be useful as therapeutic options
in the treatment of BE in experimental animals and humans.
4. Conclusions
As presented in this review, besides its pleiotropic activities in many systems including the
cardiovascular, neurological, and endocrine systems (Figure 3), melatonin exerts a potent protective
activity against endogenous (acid, pepsin) and exogenous (alcohol, NSAIDs, stress) damaging factors
affecting the GI-tract. Melatonin has been shown to afford esophagoprotection against acute esophageal
injury from acid and alkaline reflux in animals, but whether melatonin supplementation can protect
patients with GERD from esophageal erosions and BE, and from developing neoplasia in humans,
requires further clinical trials. This issue is of critical importance especially for older patients who are
at higher risk of complications from persistent GERD, a disease which affects the cost-effectiveness of
drug therapy, and further research should include strategies to reduce the financial cost of medical
care and hospitalization in elderly.
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Konturek, P.C.; Cześnikiewicz-Guzik, M.; Gzhegotsky, M.R.; et al. Protective influence of melatonin against
acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J. Physiol. Pharmacol. 2007,
58, 371–387.
82. Hamaguchi, M.; Fujiwara, Y.; Takashima, T.; Hayakawa, T.; Sasaki, E.; Shiba, M.; Watanabe, T.; Tominaga, K.;
Oshitani, N.; Matsumoto, T.; et al. Increased expression of cytokines and adhesion molecules in rat chronic
esophagitis. Digestion 2003, 68, 189–197. [CrossRef] [PubMed]
83. Klinkenberg-Knol, E.C.; Nelis, F.; Dent, J.; Snel, P.; Mitchell, B.; Prichard, P.; Lloyd, D.; Havu, N.; Frame, M.H.;
Romàn, J.; et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Efficacy,
safety, and influence on gastric mucosa. Gastroenterology 2000, 118, 661–669. [CrossRef]
84. Abdalla, S.I.; Lao-Sirieix, P.; Novelli, M.R.; Lovat, L.B.; Sanderson, I.R.; Fitzgerald, R.C. Gastrin induced
cyclooxygenase-2 expression in Barrett’s carcinogenesis. Clin. Cancer Res. 2004, 10, 4784–4792. [CrossRef]
[PubMed]
85. Boeckxstaens, G.E. Alterations confined to the gastro-oesophageal junction: The relationship between low
LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract. Res. Clin. Gastroenterol. 2010, 24, 821–829.
[CrossRef] [PubMed]
86. Tan, J.; Wang, Y.; Xia, Y.; Zhang, N.; Sun, X.; Yu, T.; Lin, L. Melatonin protects the esophageal epithelial barrier
by suppressing the transcription, expression and activity of myosin light chain kinase through ERK1/2
signal transduction. Cell. Physiol. Biochem. 2014, 34, 2117–2127. [CrossRef] [PubMed]
87. Bubenik, G.A.; Konturek, S.J. Melatonin and aging: Prospects for human treatment. J. Physiol. Pharmacol.
2011, 62, 13–19. [PubMed]
88. Madalinski, M.H. Does a melatonin supplement alter the course of gastro-esophageal reflux disease? World J.
Gastrointest. Pharmacol. Ther. 2011, 2, 50–51. [CrossRef] [PubMed]
89. Klupinska, G.A.; Wisniowska-Jarosinska, M.; Harsiuk, A.; Chojnacki, C.; Stec-Michalska, K.; Błasiak, J.;
Reiter, R.J.; Chojnacki, J. Nocturnal secretion of melatonin in patients with upper digestive tract disorders.
J. Physiol. Pharmacol. 2006, 57, 41–50. [PubMed]
90. Lewy, A.J. Melatonin as a marker and phase-resetter of circadian rhythms in humans. Adv. Exp. Med. Biol.
1999, 460, 425–434. [PubMed]
91. Buscemi, N.; Vandermeer, B.; Pandya, R.; Hooton, N.; Tjosvold, L.; Hartling, L.; Baker, G.; Vohra, S.; Klassen, T.
Melatonin for treatment of sleep disorders. Evid. Rep. Technol. Assess. (Summ.) 2004, 108, 1–7.
92. Middleton, B.A.; Stone, B.M.; Arendt, J. Melatonin and fragmented sleep patterns. Lancet 1996, 348, 551–552.
[CrossRef]
Int. J. Mol. Sci. 2018, 19, 2033 16 of 16
93. Rogers, N.L.; Phan, O.; Kennaway, D.J.; Dawson, D. Effect of day time oral melatonin administration on
neurobehavioral performance in humans. J. Pineal Res. 1998, 25, 47–53. [CrossRef] [PubMed]
94. Calvo, J.R.; Guerrero, J.M.; Osuna, C.; Molinero, P.; Carrillo-Vico, A. Melatonin triggers Crohn’s disease
symptoms. J. Pineal Res. 2002, 32, 277–278. [PubMed]
95. Acuna-Castroviejo, D.; Escames, G.; Venegas, C.; Díaz-Casado, M.E.; Lima-Cabello, E.; López, L.C.;
Rosales-Corral, S.; Tan, D.X.; Reiter, R.J. Extrapineal melatonin: Sources, regulation, and potential functions.
Cell. Mol. Life Sci. 2014, 71, 2997–3025. [CrossRef] [PubMed]
96. Triadafilopoulos, G. Proton pomp inhibitors for Barrett’s oesophagus. Gut 2000, 46, 144–146. [CrossRef]
[PubMed]
97. Haigh, C.R.; Attwood, S.E.; Thompson, D.G.; Jankowski, J.A.; Kirton, C.M.; Pritchard, D.M.; Varro, A.;
Dimaline, R. Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor.
Gastroenterology 2003, 124, 615–625. [CrossRef] [PubMed]
98. Miyazaki, Y.; Shinomura, Y.; Tsutsui, S.; Zushi, S.; Higashimoto, Y.; Kanayama, S.; Higashiyama, S.;
Taniguchi, N.; Matsuzawa, Y. Gastrin induces heparin-binding epidermal growth factor-like growth factor in
rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology 1999, 116, 78–89. [CrossRef]
99. Sawaoka, H.; Tsuji, S.; Tsuji, M.; Gunawan, E.S.; Nakama, A.; Takei, Y.; Nagano, K.; Matsui, H.; Kawano, S.;
Hori, M. Expression of the cyclooxygenase-2 gene in gastric epithelium. J. Clin. Gastroenterol. 1997, 25,
S105–S110. [CrossRef] [PubMed]
100. Sawaoka, H.; Tsuji, S.; Tsuji, M.; Gunawan, E.S.; Kawai, N.; Sasaki, Y.; Hori, M.; Kawano, S. Involvement
of cyclooxygenase-2 in proliferation and morphogenesis induced by transforming growth factor alpha in
gastric epithelial cells. Prostaglandins Leukot. Essent. Fatty Acids 1999, 61, 315–322. [CrossRef] [PubMed]
101. Rybak, A.; Pesce, M.; Thapar, N.; Borrelli, O. Gastro-esophageal reflux in children. Int. J. Mol. Sci. 2017,
18, 1671. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
